Results 171 to 180 of about 306,297 (267)

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source

A One-Year Retrospective Observational Study of an Occupational Medicine Outpatient Clinic in a City Hospital. [PDF]

Ann Glob Health
Hasanli YS.
europepmc   +1 more source

[Outpatient clinics].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1997
openaire   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

British Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem, Mohannad N. AbuHaweeleh, Humam Emad Rajha, Mhd Osama Rahhal, Ahmad Hamdan, Lina Naseralallah   +5 more
wiley   +1 more source

Health Distress and Challenges in Patients With Myeloproliferative Neoplasms During Follow-Up Consultations at the Outpatient Clinic: A Phenomenological Study. [PDF]

Cancer Rep (Hoboken)
Liu Y, Zhao J, Zhang Q, Gao Q, Cao Y, He J, Han L, Wang Y, Yang Q, Xie W.   +9 more
europepmc   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Suicidality and associated factors among people living with mental illness attending an outpatient clinic at a tertiary hospital in Uganda. [PDF]

BMC Psychiatry
Alol E, Favina A, Ashaba S, Rukundo GZ.
europepmc   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Neurological long COVID in the outpatient clinic: Is it so long? [PDF]

Eur J Neurol
Grisanti SG, Garbarino S, Bellucci M, Schenone C, Candiani V, Di Lillo S, Campi C, Barisione E, Aloè T, Tagliabue E, Serventi A, Pesce G, Massucco S, Cabona C, Lechiara A, Uccelli A, Schenone A, Piana M, Benedetti L.   +18 more
europepmc   +1 more source